gmp
gmp

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Santhera Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EXTRACTABLES & LEACHABLES SUMMIT

              Participation Not Confirmed

              Update your events

              Santhera and Cold Spring Harbor Laboratory to Investigate Lonodelestat in COVID-19-related Acute Respiratory Distress Syndrome

              Contact the Supplier

              Lead Product(s): Lonodelestat

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: CSHL

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 27, 2020

              Details:

              Santhera will provide lonodelestat and intellectual support for the scientists at CSHL who will conduct the non-clinical research program.

              Light Chain Bioscience

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EXTRACTABLES & LEACHABLES SUMMIT

              Participation Not Confirmed

              Update your events

              Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders

              Contact the Supplier

              Lead Product(s): NI-0101

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Edesa Biotech

              Deal Size: $372.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 20, 2020

              Details:

              The companies singed this exclusive worldwide license to develop and commercialize two Phase 2-ready biologic drug candidates for all therapeutic, prophylactic and diagnostic applications.

              PharmaCompass__DigitalAd